These findings have clear implications for IL-2 as a therapeutic in autoimmunity and other inflammatory settings, and may inform future endeavors to design synthetic IL-2 or low-dose IL-2 treatment protocols, which have shown promise in clinical trials46–48. The gene discussed is IL2; the disease is Autoimmunity.